Intercept’s Early NASH Efforts Will Stress Advanced Fibrosis

Intercept said its commercial groundwork in NASH centered on identifying doctors who treat patients with advanced fibrosis and talking to payers about the importance of preventing cirrhosis.

SC1912_Product Launch_380643976_1200.jpg
Intercept outlined its launch plans for OCA in NASH

Intercept Pharmaceuticals Inc. believes it has identified the sweet spot for its initial marketing focus in non-alcoholic steatohepatitis (NASH) as patients with advanced fibrosis, and that the specialist physicians who will be its target customers are on board. Further, the firm said early talks with payers indicate they agree that treating NASH patients with advanced fibrosis and trying to avoid progression to cirrhosis is a sensible strategy both medically and economically.

Intercept outlined its commercial strategy during an investor presentation on 16 December, just after revealing that the US Food and...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Strategy

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.